Skip to main content

Table 1 Population characteristics at baseline and comparison between patients with/without OHSI, and between OHSI patients and their paired controls

From: Early referral and control of disease’s flares prevent Orthopedic and Hand Surgery Indication (OHSI) in a dynamic cohort of Hispanic early rheumatoid arthritis patients

  Population (N = 185) Patients with OHSI (N = 12) Patients without OHSI (N = 173) OHSI-paired controls (N = 48) p1 p2
Female sex, N° (%) of patients 162 (87.6) 11 (91.7) 151 (87.3) 44 (99.7) 1 1
(Mean ± SD) Age at cohort inclusion, years 38.5 ± 12.9 42 ± 15.6 38.3 ± 12.7 42 ± 14.9 0.33 1
Medium-low socioeconomic level, N° (%) of patients 165 (89.2) 11 (91.7) 154 (89) 43 (89.6) 1 1
(Mean ± SD) Years of formal education 11.2 ± 3.9 10.2 ± 4.3 11.3 ± 3.9 10.8 ± 4.2 0.32 0.66
Disease duration, months 5.3 (3. 3-7.0) 7.5 (6. 2-9.3) 5 (2. 9-7.4) 5 (2. 9-7.4) 0.02 0.02
N° (%) of patients with RF 152 (82.8) 11 (91.7) 141 (81.5) 44 (99) 0.7 1
N° (%) of patients with ACCP 158 (85.9) 12 (100) 146 (84.9) 43 (91.5) 0.22 0.6
N° (%) of patients with erosions 18 (9.7) 2 (16.7) 16 (9.2) 5 (10.4) 0.33 0.62
DAS28 5.9 (4.8-6.9) 7 (5.4-7.7) 6.3 (4.9-7.5) 6.3 (4.9-7.5) 0.27 0.27
Physician-VAS 36 (36–49) 51 (31-68) 41 (30-52) 41 (30-51.5) 0.23 0.23
CRP, mg/dL 0.7 (0.3-2.5) 3.6 (0.5-7.1) 1.2 (0.3-2.3) 1.2 (0.3-2.3) 0.06 0.06
ESR, mm/H 11 (12-39) 42 (19-74) 26 (15-49) 26 (15. 3-49) 0.14 0.14
Charlson Score 1 (1-1) 1 (1-1) 1 (1-1) 1 (1-1) 0.18 0.12
HAQ (0–3) 1.4 (0.9-2.1) 1.4 (1-2.3) 1.4 (0.9-2) 1.4 (0.9-2) 0.73 0.73
SF-36 (0–100) 38 (27-55) 33 (24-56) 34 (26-57) 33.8 (26.4-57.4) 0.94 0.94
Patient-overall disease-VAS 53 (33-76) 71 (41–92) 62 (34-78) 62 (34-78) 0.29 0.29
Pain-VAS 50 (31-73) 61 (46–98) 52 (33-78) 52 (33.3-77.8) 0.48 0.48
N° (%) of patients with DMARDs 101 (54.6) 7 (58.3) 94 (54.3) 19 (39.6) 1 1
N° (%) of patients with corticosteroids 72 (38.9) 4 (33.3) 68 (39.3) 15 (31.3) 0.77 1
  1. OHSI orthopaedic and hand surgery indication, N number, SD standard deviation, RF rheumatoid factor, ACCP antibodies to cyclic citrullinated peptides, DAS disease activity score (28 joints evaluated), VAS visual analogue scale, CRP C reactive protein, ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire, SF-36 short form 36, P1 Comparison between patients with vs. without OHSI, P2 Comparison between patients with OHSI vs. paired controls
  2. Data presented as median (25th–75th IQR) unless otherwise indicated